Pharmacogenomics of Medication-Induced Weight Gain and Antiobesity Medications.
Obesity (Silver Spring)
; 29(2): 265-273, 2021 02.
Article
em En
| MEDLINE
| ID: mdl-33491309
ABSTRACT
Obesity is a chronic, multifactorial disease associated with a large number of comorbidities. The clinical management of obesity involves a stepwise integrated approach, beginning with behavioral and lifestyle modification, followed by antiobesity medications, endobariatric procedures, and bariatric surgery. Weight gain and subsequent obesity are common side effects of medications, such as prednisone or antipsychotics. In this era of precision medicine, it is essential to identify patients at the highest risk of weight gain as a result of medication use. Pharmacogenomics could play an important role in obesity management by optimizing use of antiobesity medications as well as minimizing adverse weight gain. This review aims to provide a comprehensive analysis of the current literature on the role of pharmacogenomics in obesity and medication-induced weight gain. In summary, there are more robust studies of medication associated with weight gain and pharmacogenomics, and more studies are needed to understand the role of pharmacogenomics in antiobesity medications.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Aumento de Peso
/
Fármacos Antiobesidade
/
Obesidade
Limite:
Humans
Idioma:
En
Revista:
Obesity (Silver Spring)
Assunto da revista:
CIENCIAS DA NUTRICAO
/
FISIOLOGIA
/
METABOLISMO
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Estados Unidos